TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene is differentiated by its “superior” efficacy and safety to standard of care in BCG-unresponsive, non-muscle invasive bladder cancer, with intravesical administration that is already deployed in practices. TD expects the management team to successfully launch cretostimogene in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON: